Trial · NCT07882875
Clinical Significance of Internal Carotid Artery Dolichoarteriopathy
NCT07882875, Not yet recruiting, Kuban State Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Significance of Internal Carotid Artery Dolichoarteriopathy. Trials, record NCT07882875. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07882875
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Significance of Internal Carotid Artery Dolichoarteriopathy
- NCT number
- NCT07882875
- Status
- Not yet recruiting
- Enrollment
- 560 participants, estimated
- Lead sponsor
- Kuban State Medical University
- Conditions
- Internal Carotid Artery Dolichoarteriopathy, Carotid Artery Tortuosity
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Ipsilateral Ischemic Stroke and/or Transient Ischemic Attack | From baseline through 24 months | Number and proportion of participants who experience at least one ipsilateral ischemic stroke and/or transient ischemic attack during prospective follow-up. Events will be evaluated using clinical and available neuroimaging data, with consideration of alternative cerebrovascular mechanisms. |
| Secondary | Change in Montreal Cognitive Assessment (MoCA) Score | Baseline through 24 months | Change from baseline in cognitive performance measured using the Montreal Cognitive Assessment (MoCA). Higher scores indicate better cognitive performance. |
| Secondary | Change in Frontal Assessment Battery (FAB) Score | Baseline through 24 months | Change from baseline in frontal and executive cognitive function measured using the Frontal Assessment Battery (FAB). Higher scores indicate better frontal and executive function. |
| Secondary | Change in Trail Making Test (TMT) Performance | Baseline through 24 months | Change from baseline in Trail Making Test performance measured by completion time during prospective follow-up. Longer completion time indicates poorer test performance. |
| Secondary | New or Progressive Structural Cerebral Abnormalities on MRI | Baseline through 24 months | Number and proportion of participants with at least one new or progressive structural cerebral abnormality on magnetic resonance imaging compared with baseline imaging, including predefined study-relevant signs of cerebral ischemic or vascular injury. |
| Secondary | Change in Serum Neurofilament Light Chain Level | Baseline through 24 months | Change from baseline in serum neurofilament light chain (sNfL) concentration during prospective follow-up. |
| Secondary | Change in Glial Fibrillary Acidic Protein Level | Baseline through 24 months | Change from baseline in circulating glial fibrillary acidic protein (GFAP) concentration during prospective follow-up. |
| Secondary | Change in Anti-NR2 Antibody Level | Baseline through 24 months | Change from baseline in circulating anti-NR2 antibody level during prospective follow-up. |
| Secondary | Change in Modified Rankin Scale (mRS) Score | Baseline through 24 months | Change from baseline in functional status measured using the modified Rankin Scale (mRS). Higher scores indicate greater disability. |
| Secondary | Change in SF-36 Health-Related Quality of Life Score | Baseline through 24 months | Change from baseline in health-related quality of life measured using the 36-Item Short Form Health Survey (SF-36) according to the study assessment schedule. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07882875
GET https://conductscience.org/api/trials/v1/NCT07882875/registered